Approval Year
Substance Class |
Protein
Created
by
admin
on
Edited
Tue Apr 01 18:39:44 GMT 2025
by
admin
on
Tue Apr 01 18:39:44 GMT 2025
|
Protein Type | RECEPTOR |
Protein Sub Type | |
Sequence Origin | HUMAN |
Sequence Type | COMPLETE |
Record UNII |
SKEU5X23RI
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
P34972
Created by
admin on Tue Apr 01 18:39:45 GMT 2025 , Edited by admin on Tue Apr 01 18:39:45 GMT 2025
|
PRIMARY | |||
|
SKEU5X23RI
Created by
admin on Tue Apr 01 18:39:45 GMT 2025 , Edited by admin on Tue Apr 01 18:39:45 GMT 2025
|
PRIMARY | |||
|
P34972
Created by
admin on Tue Apr 01 18:39:45 GMT 2025 , Edited by admin on Tue Apr 01 18:39:45 GMT 2025
|
PRIMARY |
Glycosylation Type | HUMAN |
Glycosylation Link Type | Site |
---|---|
N | 1_11 |
Related Record | Type | Details | ||
---|---|---|---|---|
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
Selectivity of around 220 times for CB2 over CB1 receptors.
Ki
|
||
|
AGONIST -> TARGET |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB2
EC50
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
A potent agonist
|
||
|
AGONIST -> TARGET |
IC50
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB2
EC50
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
INVERSE AGONIST->TARGET |
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
Strong agonist
EC50
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB2
EC50
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB2
EC50
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
MN-25 (UR-12) acts as a reasonably selective agonist of peripheral cannabinoid receptors. It has moderate affinity for CB2 receptors with a Ki of 11 nM.
Ki
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
EC50
|
||
|
INVERSE AGONIST->TARGET |
?69% of basal activity
EC50
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB2
EC50
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
IC50
|
||
|
AGONIST -> TARGET |
Selectivity over the psychoactive CB1 receptor
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB2
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB2
EC50
|
||
|
AGONIST -> TARGET |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB2
EC50
|
||
|
INHIBITOR -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Emax 65% of CP55940
EC50
|
||
|
LIGAND->TARGET | |||
|
AGONIST -> TARGET |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB2
EC50
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB2
EC50
|
||
|
AGONIST -> TARGET |
Emax=68.8
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET | |||
|
INVERSE AGONIST->TARGET | |||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
High selectivity for CB2 (CB1 IC50/CB2 IC50 = 1400),
EC50
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB2
EC50
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB2
EC50
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB2
EC50
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Emax=68.8
EC50
|
||
|
RADIOLIGAND->TARGET |
Highly selective. Binding to the CB1 receptor KihCB1 >1000 nM
BINDING
Ki
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
|
||
|
RADIOLIGAND->TARGET |
Kd
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB2
EC50
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
The primary endogenous ligand for the CB2
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB2
EC50
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
WEAK AGONIST->TARGET |
Ki
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB2
EC50
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB2
EC50
|
||
|
AGONIST -> TARGET |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB2
EC50
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
RADIOLIGAND->TARGET |
Ki
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB2
EC50
|
||
|
AGONIST -> TARGET |
Mouse AtT-20 neuroblastoma cells stably transfected with human CB2
EC50
|
||
|
AGONIST -> TARGET |
Ki
|
Structural Modifications
Modification Type | Location Site | Location Type | Residue Modified | Extent | Fragment Name | Fragment Approval |
---|---|---|---|---|---|---|
AMINO ACID SUBSTITUTION | [1_335] [1_336] [1_352] | DEXFOSFOSERINE | VI4F0K069V | |||
AMINO ACID SUBSTITUTION | [1_338] | THREONINE PHOSPHATE | 3L4WX7B1EI |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Molecular Formula | CHEMICAL |
|
||||
MOL_WEIGHT | CHEMICAL |
|